Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.45 | ||
| PEG Ratio (f) | 1.06 | ||
| EPS Growth (f) | 15.72% | ||
| Dividend Yield (f) | 2.84% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.49 | ||
| Price to Tang. Book | 2.51 | ||
| Price to Free Cashflow | 37.55 | ||
| Price to Sales | 2.54 | ||
| EV to EBITDA | 8.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.34% | ||
| Return on Equity | 9.82% | ||
| Operating Margin | 18.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 352,246 | 398,371 | 442,233 | 495,558 | 496,826 | 530,234 | 539,576 | 9.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +4.4 | +22.26 | +19.09 | -18.29 | +15.36 | +7.09 | +16.9 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The Company operates in Japan and overseas.
Directors
- Masashi Miyamoto CHM (66)
- Takeyoshi Yamashita VPR (64)
- Yasuo Fujii OTH
- Toshiyuki Kurata OTH
- Shoko Itagaki OTH
- Kenji Shibata DRC (59)
- Yoshihisa Suzuki NEC (71)
- Yoshiko Mori CCO
- Abdul Mullick PRE (58)
- Daisuke Fujiwara DRC (55)
- Hiroshi Kanno IND (67)
- Yukiko Ito IND (47)
- Mitsuru Kameyama OTH
- Colin Sims OTH
- Koji Igarashi CFO
- Last Annual
- December 31st, 2025
- Last Interim
- September 30th, 2026
- Incorporated
- July 1st, 1949
- Public Since
- August 22nd, 1949
- No. of Shareholders
- 30,109
- No. of Employees
- 5,161
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange
- Shares in Issue
- 523,584,710

- Address
- 17F,, CHIYODA-KU, 100-0004
- Web
- https://www.kyowakirin.co.jp/index.html
- Phone
- +81 null352057200
- Auditors
- KPMG AZSA LLC
Latest News for 4151
Upcoming Events for 4151
Dividend For 4151.T - 35.0000 JPY
Full Year 2026 Kyowa Kirin Co Ltd Earnings Release
Kyowa Kirin Co Ltd Annual Shareholders Meeting
Q1 2027 Kyowa Kirin Co Ltd Earnings Release
Similar to 4151
ASKA Pharmaceutical Holdings
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings
Tokyo Stock Exchange
CanBas
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 11:42 UTC, shares in Kyowa Kirin are trading at ¥2,585. This share price information is delayed by 15 minutes.
Shares in Kyowa Kirin last closed at ¥2,585 and the price had moved by +3.48% over the past 365 days. In terms of relative price strength the Kyowa Kirin share price has underperformed the Nikkei 225 Index by -13.21% over the past year.
The overall consensus recommendation for Kyowa Kirin is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Kyowa Kirin dividend yield is 2.59% based on the trailing twelve month period.
Last year, Kyowa Kirin paid a total dividend of ¥67, and it currently has a trailing dividend yield of 2.59%.Looking ahead, shares in Kyowa Kirin are due to go ex-dividend on 2026-12-29 and the next dividend pay date is 2027-03-23.
Kyowa Kirin are due to go ex-dividend on 2026-12-29 and the next dividend pay date is 2027-03-23. The historic dividend yield on Kyowa Kirin shares is currently 2.59%.
To buy shares in Kyowa Kirin you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥2,585, shares in Kyowa Kirin had a market capitalisation of ¥1tn.
Here are the trading details for Kyowa Kirin:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4151
Based on an overall assessment of its quality, value and momentum Kyowa Kirin is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kyowa Kirin is ¥2,276. That is 11.97% below the last closing price of ¥2,585.
Analysts covering Kyowa Kirin currently have a consensus Earnings Per Share (EPS) forecast of ¥156 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kyowa Kirin. Over the past six months, its share price has outperformed the Nikkei 225 Index by +8.49%.
As of the last closing price of ¥2,585, shares in Kyowa Kirin were trading +4.54% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kyowa Kirin PE ratio based on its reported earnings over the past 12 months is 14.45. The shares last closed at ¥2,585.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kyowa Kirin's management team is headed by:
- Masashi Miyamoto - CHM
- Takeyoshi Yamashita - VPR
- Yasuo Fujii - OTH
- Toshiyuki Kurata - OTH
- Shoko Itagaki - OTH
- Kenji Shibata - DRC
- Yoshihisa Suzuki - NEC
- Yoshiko Mori - CCO
- Abdul Mullick - PRE
- Daisuke Fujiwara - DRC
- Hiroshi Kanno - IND
- Yukiko Ito - IND
- Mitsuru Kameyama - OTH
- Colin Sims - OTH
- Koji Igarashi - CFO





